Infinity Pharmaceuticals has been granted a patent for a method to treat hematological cancers using a combination of specific inhibitors. The method involves administering Compound 1 and ABT-199 at specified doses for various types of cancers like CLL, DLBCL, and FL. GlobalData’s report on Infinity Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Infinity Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Infinity Pharmaceuticals's grant share as of May 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of hematological cancer using specific pharmaceutical compositions
A recently granted patent (Publication Number: US11944631B2) discloses a method for treating hematological cancers in human subjects by administering a specific compound, Compound 1, concurrently with or following another compound, ABT-199. The dosage ranges for Compound 1 and ABT-199 are specified in the claims, with Compound 1 administered at doses between 15 mg to 75 mg and ABT-199 at doses ranging from 10 mg to 400 mg. The hematological cancers targeted by this method include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), indolent NHL (iNHL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), T-cell lymphoma (TCL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), follicular lymphoma (FL), and Richter's syndrome.
Furthermore, the patent claims detail variations in the administration of Compound 1 and ABT-199, including different dosages, frequencies, and combinations for treating hematological cancers. The method outlined in the patent involves a two-step process where Compound 1 is administered for a specific period, followed by a combination therapy with ABT-199. Specific dosages and administration frequencies are highlighted in the claims, emphasizing the treatment of various hematological cancers such as DLBCL, iNHL, FL, MCL, T-cell lymphoma, CLL, SLL, CLL/SLL, and Richter's syndrome, particularly in cases of relapsed or refractory cancers. This patent provides a structured approach to treating hematological cancers, offering potential therapeutic options for patients in need of effective treatment strategies.
To know more about GlobalData’s detailed insights on Infinity Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
